Chardan Capital Reiterates “Buy” Rating for GenSight Biologics (OTCMKTS:GSGTF)

GenSight Biologics (OTCMKTS:GSGTF)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a report issued on Tuesday, The Fly reports.

Shares of GenSight Biologics stock opened at $3.10 on Tuesday.

GenSight Biologics Company Profile

GenSight Biologics SA, a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms.

Featured Story: Market Perform

The Fly

Receive News & Ratings for GenSight Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenSight Biologics and related companies with MarketBeat.com's FREE daily email newsletter.